

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
0075/0076	Boehringer Mannheim UK (Pharmaceuticals) Limited	Torem 200 mg Tablet	Toraseamide HSE 200 mg	Prescription Only Medicine Indicated solely for patients with markedly reduced renal function, to maintain residual excretion of urine in severe renal failure, during dialysis if there is still an appreciable residual excretion of urine (more than 200 ml/24 hours), when there is accumulation of fluid in tissues and/or body cavities, and in Nephrotic Syndrome with markedly restricted renal function, eg in Lupus Erythematosus, Chronic Glomerulonephritis or Diabetic Glomerulosclerosis (Kimmelstiel-Wilson Syndrome).	26th April, 1994
0075/0079	Boehringer Mannheim UK (Pharmaceuticals) Limited	Torem Injection 200 mg/20 ml	Toraseamide Sodium Salt* HSE 212.62 mg * Equivalent to 200 mg Toraseamide	Prescription Only Medicine Indicated solely for patients with markedly reduced renal function. Used in threatening or existing acute renal failure to maintain fluid excretion and to facilitate parenteral feeding as long as residual filtration is present. To maintain residual excretion of urine in severe renal failure, and during dialysis if there is still an appreciable residual excretion of urine (more than 200 ml/24 hours). When there is accumulation of fluid in tissues and/or body cavities, and in Nephrotic Syndrome with markedly restricted renal function, eg in Lupus Erythematosus, Chronic Glomerulonephritis or Diabetic Glomerulosclerosis (Kimmelstiel-Wilson Syndrome).	26th April, 1994
0075/0083	Boehringer Mannheim UK (Pharmaceuticals) Limited	Recormon 5000 N	Erythropoietin HSE 5000 IU	Prescription Only Medicine For use in the correction of erythropoietin deficiency in patients with renal anaemia. For use in patients scheduled for elective surgery to increase the yield of autologous blood.	5th April, 1994
0075/0084	Boehringer Mannheim UK (Pharmaceuticals) Limited	Recormon 10000 N	Erythropoietin HSE 10000 IU	Prescription Only Medicine Same as in PL 0075/0083.	5th April, 1994
0116/0252	Baxter Healthcare Limited	Nutrineal PD2 with 1.1% Amino Acids	L-Tyrosine USP.03% w/v L-Tryptophan FRP.027% w/v L-Phenylalanine USP.057% w/v L-Threonine USP.0646% w/v L-Serine USP.051% w/v L-Proline USP.0595% w/v Glycine USP.051% w/v L-Alanine USP.0951% w/v L-Valine USP.1393% w/v L-Methionine USP.085% w/v L-Isoleucine USP.085% w/v L-Leucine USP.102% w/v L-Lysine (Hydrochloride) USP.0955% w/v L-Histidine USP.0714% w/v L-Arginine USP.1071% w/v Calcium Chloride EP.0257% w/v Magnesium Chloride EP.0051% w/v Sodium Lactate FRP.448% w/v Sodium Chloride EP.538% w/v	Prescription Only Medicine Nutritional supplement for Malnourished renal failure patients (albumin concentration lower than 35g/l) being maintained on peritoneal dialysis.	13th April, 1994
0116/0253	Baxter Healthcare Limited	Nutrineal PD4 with 1.1% Amino Acids	L-Tyrosine USP.03% w/v L-Tryptophan FRP.027% w/v L-Phenylalanine USP.057% w/v L-Threonine USP.0646% w/v L-Serine USP.051% w/v L-Proline USP.0595% w/v Glycine USP.051% w/v L-Alanine USP.0951% w/v L-Valine USP.1393% w/v L-Methionine USP.085% w/v L-Isoleucine USP.085% w/v L-Leucine USP.102% w/v L-Lysine (Hydrochloride) USP.0955% w/v L-Histidine USP.0714% w/v L-Arginine USP.1071% w/v Calcium Chloride EP.0184% w/v Magnesium Chloride EP.0051% w/v Sodium Lactate FRP.448% w/v Sodium Chloride EP.538% w/v	Prescription Only Medicine Same as in PL 0116/0252	13th April, 1994
0142/0380	A H Cox and Company Limited T/A Cox Pharmaceuticals	Bendrofluazide Tablets BP 2.5 mg	Bendrofluazide EP 2.50 mg	Prescription Only Medicine Cases where the reduction of fluid retention by diuresis is required; Oedema of cardiac, renal or hepatic origin; premenstrual oedema; Toxaemia of pregnancy, Iatrogenic oedema and all other	27th June, 1994